Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

RegulatorypositiveBelapectinPositive

AI Analysis

Summary

Galectin Therapeutics announced positive feedback from an in-person Type C Meeting with the FDA regarding belapectin for patients with MASH cirrhosis and portal hypertension. This regulatory milestone provides guidance for the development program moving forward.

Outcome Details

Positive Type C Meeting feedback from FDA

Importance:6/10

Sentiment:

0.75

FDAType C MeetingLiver DiseaseRegulatoryBelapectin

Related Companies

$GALT

Read the original article

Published by Drugs.com Clinical Trial Results on June 23, 2026 3:07 AM

Read Original